This product is suitable for use with the?Maxpar? Metal Labeling Kits.?For metal labeling using Maxpar? Ready antibodies,?proceed directly to the step to Partially Reduce the Antibody by adding 100 ?l of Maxpar? Ready antibody to 100 ?l of 4 mM TCEP-R in a 50 kDa filter and continue with the protocol. Always refer to the latest version of Maxpar? User Guide when conjugating Maxpar? Ready antibodies.

ELISA^1-4,11,14 or ELISPOT⁵ Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-? (Cat. No. 575309) as the standard.
ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-? (Cat. No. 575309) as the standard. The LEAF? purified antibody is suggested for ELISPOT capture (Cat. No. 505812).
Flow Cytometry^7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-?-producing cells within mixed cell populations.
Neutralization^1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-?. The LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for neutralization of mouse IFN-? bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF? purified antibodies (Endotoxin <0.01 EU/?g).
Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections^6,22,23, and immunocytochemistry.
Note: For testing mouse IFN-? in serum, plasma or supernatant, BioLegend's ELISA Max? Sets (Cat. No. 430801 to 430806) are specially developed and recommended.

Maxpar? is a registered trademark of Standard BioTools Inc.

1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut)
2. Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut)
3. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut)
4. Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA)
5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT)
6. Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC)
7. Ferrick D, et al. 1995. Nature 373:255. (FC)
8. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
9. Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut)
10. DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut)
11. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
12. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
13. Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed
14. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
15. Montfort M, et al.2004. J. Immunol. 173:4084. PubMed
16. Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed
17. Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed
18. Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed
19. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
20. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed
21. Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed
22. Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC)
23. Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)

1. McDonald B, et al. 2020. Cell Host Microbe. 28(5):660-668.e4. PubMed

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.